On the fly News and insights, exclusive to thefly.com

CVM

CEL-SCI

$9.42 /

-6.95 (-42.46%)

15:29
02/26/20
02/26
15:29
02/26/20
15:29

CEL-SCI off lows after CEO letter to shareholders

Shares of CEL-SCI, which dropped to as low as $7.20 earlier this afternoon, have rebounded somewhat and are now trading at $9.42 following a letter to shareholders from CEL-SCI CEO Geert Kersten which said that Multikine, which has been in Phase 3 trial since 2011, is likely producing "some kind of a survival benefit." Despite the uptick, shares of CEL-SCI are still down over 42% on the day, having opened at $15.76.

  • 26

    Feb

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.